AKT1 and cardiac hypertrophy: Moreover, as the ArQule allosteric AKT inhibitor, ARQ 092, is orally bioavailable, potent and selective, use of this inhibitor may be more readily tolerated and accepted by patients for treatment of NSML-associated cardiac hypertrophy.